LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
Last week, CMS announced that it was eliminating certain waivers and regulatory flexibility it provided when the COVID-19 pandemic began.
While labs...
The kinder, gentler version of the standard removes key controversial elements, such as mandating vaccination for employees.
The model, meant to start Jan. 1 of this year, had already been delayed over concerns from key stakeholders, and its start date is now TBD
Key stakeholders hold a briefing to inform lawmakers of the impact of potential new regulations for laboratory developed testing procedures.
The White House recently provided on update on agencies’ progress in carrying out EO to boost Medicaid and the Affordable Care Act
On Feb. 23, the...
Webinar will give you the chance to learn about recent changes at G2 and ask the editorial team any questions you may have.
The good news:...